GlassScriptPhysician profile
Eric Christian Drew
NPI 1578539839
$2,400.07
in general payments reported to CMS, 2019-2025
24 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $347 · 2020: $160 · 2021: $308 · 2022: $440 · 2023: $555 · 2024: $427 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $699.84 | 2021-2025 | Botox, Ubrelvy, Duopa |
| Teva Pharmaceuticals USA, INC. | $301.66 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Biohaven Pharmaceuticals, INC. | $187.88 | 2020-2021 | |
| Medtronic, INC. | $180.59 | 2022-2025 | Percept PC Brainsense |
| Pfizer INC. | $154.43 | 2023 | |
| Stryker Corporation | $140.82 | 2022 | |
| Allergan, INC. | $126.72 | 2019-2022 | |
| Penumbra, INC. | $121.46 | 2019 | |
| Biogen, INC. | $67.32 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $62.13 | 2020-2025 | Nuplazid |
| Kyowa Kirin, INC. | $59.48 | 2020-2023 | Nourianz |
| Acorda Therapeutics, INC | $44.27 | 2019 | |
| Life Molecular Imaging LTD | $28.96 | 2024 | Neuraceq |
| Averitas Pharma INC. | $27.10 | 2023 | Qutenza |
| Eisai INC. | $24.94 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $24.13 | 2019 | |
| Lundbeck LLC | $23.66 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.01 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $19.86 | 2025 | Rexulti |
| Tersera Therapeutics LLC | $18.55 | 2019 | |
| Avion Pharmaceuticals | $18.52 | 2023 | Dhivy |
| Globus Medical, INC. | $17.19 | 2025 | Senza |
| Abbott Laboratories | $16.39 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.